The DOI matches its Crossref record; 188 of the 188 references it cites were found in a registry or an index.
Lipid nanoparticles for nucleic acid delivery: Current perspectives
Abstract
Nucleic Acid (NA) based therapeutics are poised to disrupt modern medicine and augment traditional pharmaceutics in a meaningful way. However, a key challenge to advancing NA therapies into the clinical setting and on to the market is the safe and effective delivery to the target tissue and cell. Lipid Nanoparticles (LNP) have been extensively investigated and are currently the most advanced vector for the delivery of NA drugs, as evidenced by the approval of Onpattro for treatment of Amyloidosis in the US and EU in 2018. This article provides a comprehensive review of the state-of-the-art for LNP technology. We discuss key advances in the design and development of LNP, leading to a broad range of therapeutic applications. Finally, the current status of this technology in clinical trials and its future prospects are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
Daneman, R., & Prat, A. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a020412 · Cited by 3,437
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488
Cheng, Q., Wei, T., Farbiak, L., Johnson, L. T., Dilliard, S. A., & Siegwart, D. J. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0669-6 · Cited by 2,383
Rational design of cationic lipids for siRNA delivery
Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W. Y., Stebbing, D., Crosley, E. J., Yaworski, E., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1602 · Cited by 1,822
Gilleron, J., Querbes, W., Zeigerer, A., Borodovsky, A., Marsico, G., Schubert, U., Manygoats, K., Seifert, S., Andree, C., Stöter, M., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2612 · Cited by 1,681
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
Akinc, A., Maier, M. A., Manoharan, M., Fitzgerald, K., Jayaraman, M., Barros, S., Ansell, S., Du, X., Hope, M. J., Madden, T. D., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0591-y · Cited by 1,636
Seeger, C., & Mason, W. S. (2000) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.64.1.51-68.2000 · Cited by 1,451
RNAi-mediated gene silencing in non-human primates
Zimmermann, T. S., Lee, A. C. H., Akinc, A., Bramlage, B., Bumcrot, D., Fedoruk, M. N., Harborth, J., Heyes, J. A., Jeffs, L. B., John, M., et al. (2006) · Nature · doi:10.1038/nature04688 · Cited by 1,357
Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo
Jayaraman, M., Ansell, S. M., Mui, B. L., Tam, Y. K., Chen, J., Du, X., Butler, D., Eltepu, L., Matsuda, S., Narayanannair, J. K., et al. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201203263 · Cited by 1,267
Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms
Akinc, A., Querbes, W., De, S., Qin, J., Frank-Kamenetsky, M., Jayaprakash, K. N., Jayaraman, M., Rajeev, K. G., Cantley, W. L., Dorkin, J. R., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.85 · Cited by 1,261
Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs
Morrissey, D. V., Lockridge, J. A., Shaw, L., Blanchard, K., Jensen, K., Breen, W., Hartsough, K., Machemer, L., Radka, S., Jadhav, V., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1122 · Cited by 1,168
A combinatorial library of lipid-like materials for delivery of RNAi therapeutics
Akinc, A., Zumbuehl, A., Goldberg, M., Leshchiner, E. S., Busini, V., Hossain, N., Bacallado, S. A., Nguyen, D. N., Fuller, J., Alvarez, R., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1402 · Cited by 1,150
Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery
Kowalski, P. S., Rudra, A., Miao, L., & Anderson, D. G. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.012 · Cited by 1,127
Safety and efficacy of RNAi therapy for transthyretin amyloidosis
Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208760 · Cited by 971
Lipid-like materials for low-dose, in vivo gene silencing
Love, K. T., Mahon, K. P., Levins, C. G., Whitehead, K. A., Querbes, W., Dorkin, J. R., Qin, J., Cantley, W., Qin, L. L., Racie, T., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910603106 · Cited by 969
Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling
Sahay, G., Querbes, W., Alabi, C., Eltoukhy, A., Sarkar, S., Zurenko, C., Karagiannis, E., Love, K., Chen, D., Zoncu, R., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2614 · Cited by 948
Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines
Hassett, K. J., Benenato, K. E., Jacquinet, E., Lee, A., Woods, A., Yuzhakov, O., Himansu, S., Deterling, J., Geilich, B. M., Ketova, T., et al. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.01.013 · Cited by 927
Modified mRNA vaccines protect against zika virus infection
Richner, J. M., Himansu, S., Dowd, K. A., Butler, S. L., Salazar, V., Fox, J. M., Julander, J. G., Tang, W. W., Shresta, S., Pierson, T. C., et al. (2017) · Cell · doi:10.1016/j.cell.2017.02.017 · Cited by 909
Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination
Pardi, N., Hogan, M. J., Pelc, R. S., Muramatsu, H., Andersen, H., DeMaso, C. R., Dowd, K. A., Sutherland, L. L., Scearce, R. M., Parks, R., et al. (2017) · Nature · doi:10.1038/nature21428 · Cited by 884
Sabnis, S., Kumarasinghe, E. S., Salerno, T., Mihai, C., Ketova, T., Senn, J. J., Lynn, A., Bulychev, A., McFadyen, I., Chan, J., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.03.010 · Cited by 820
Kauffman, K. J., Dorkin, J. R., Yang, J. H., Heartlein, M. W., DeRosa, F., Mir, F. F., Fenton, O. S., & Anderson, D. G. (2015) · Nano Letters · doi:10.1021/acs.nanolett.5b02497 · Cited by 796
The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells
Seif, F., Khoshmirsafa, M., Aazami, H., Mohsenzadegan, M., Sedighi, G., & Bahar, M. (2017) · Cell Communication and Signaling · doi:10.1186/s12964-017-0177-y · Cited by 768
History, Heterogeneity, Developmental Biology, and Functions of Quiescent Hepatic Stellate Cells
Geerts, A. (2001) · Seminars in Liver Disease · doi:10.1055/s-2001-17550 · Cited by 740
Expression of therapeutic proteins after delivery of chemically modified mRNA in mice
Kormann, M. S. D., Hasenpusch, G., Aneja, M. K., Nica, G., Flemmer, A. W., Herber-Jonat, S., Huppmann, M., Mays, L. E., Illenyi, M., Schams, A., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1733 · Cited by 733
The accelerated blood clearance (ABC) phenomenon: Clinical challenge and approaches to manage
Abu Lila, A. S., Kiwada, H., & Ishida, T. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.07.026 · Cited by 721
Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy
Oberli, M. A., Reichmuth, A. M., Dorkin, J. R., Mitchell, M. J., Fenton, O. S., Jaklenec, A., Anderson, D. G., Langer, R., & Blankschtein, D. (2017) · Nano Letters · doi:10.1021/acs.nanolett.6b03329 · Cited by 719
Andries, O., Mc Cafferty, S., De Smedt, S. C., Weiss, R., Sanders, N. N., & Kitada, T. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.051 · Cited by 701
Tabernero, J., Shapiro, G. I., LoRusso, P. M., Cervantes, A., Schwartz, G. K., Weiss, G. J., Paz-Ares, L., Cho, D. C., Infante, J. R., Alsina, M., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0429 · Cited by 698
Visualizing lipid-formulated siRNA release from endosomes and target gene knockdown
Wittrup, A., Ai, A., Liu, X., Hamar, P., Trifonova, R., Charisse, K., Manoharan, M., Kirchhausen, T., & Lieberman, J. (2015) · Nature Biotechnology · doi:10.1038/nbt.3298 · Cited by 693
Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA
Belliveau, N. M., Huft, J., Lin, P. J., Chen, S., Leung, A. K., Leaver, T. J., Wild, A. W., Lee, J. B., Taylor, R. J., Tam, Y. K., et al. (2012) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2012.28 · Cited by 685
Nonviral delivery of self-amplifying RNA vaccines
Geall, A. J., Verma, A., Otten, G. R., Shaw, C. A., Hekele, A., Banerjee, K., Cu, Y., Beard, C. W., Brito, L. A., Krucker, T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1209367109 · Cited by 675
Kulkarni, J. A., Darjuan, M. M., Mercer, J. E., Chen, S., van der Meel, R., Thewalt, J. L., Tam, Y. Y. C., & Cullis, P. R. (2018) · ACS Nano · doi:10.1021/acsnano.8b01516 · Cited by 663
Bahl, K., Senn, J. J., Yuzhakov, O., Bulychev, A., Brito, L. A., Hassett, K. J., Laska, M. E., Smith, M., Almarsson, Ö., Thompson, J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.035 · Cited by 642
Frank-Kamenetsky, M., Grefhorst, A., Anderson, N. N., Racie, T. S., Bramlage, B., Akinc, A., Butler, D., Charisse, K., Dorkin, R., Fan, Y., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805434105 · Cited by 642
Maier, M. A., Jayaraman, M., Matsuda, S., Liu, J., Barros, S., Querbes, W., Tam, Y. K., Ansell, S. M., Kumar, V., Qin, J., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.124 · Cited by 625
mRNA vaccine delivery using lipid nanoparticles
Reichmuth, A. M., Oberli, M. A., Jaklenec, A., Langer, R., & Blankschtein, D. (2016) · Therapeutic Delivery · doi:10.4155/tde-2016-0006 · Cited by 624
Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity
Whitehead, K. A., Dorkin, J. R., Vegas, A. J., Chang, P. H., Veiseh, O., Matthews, J., Fenton, O. S., Zhang, Y., Olejnik, K. T., Yesilyurt, V., et al. (2014) · Nature Communications · doi:10.1038/ncomms5277 · Cited by 615
Patisiran: First Global Approval
Hoy, S. M. (2018) · Drugs · doi:10.1007/s40265-018-0983-6 · Cited by 614
Sato, Y., Murase, K., Kato, J., Kobune, M., Sato, T., Kawano, Y., Takimoto, R., Takada, K., Miyanishi, K., Matsunaga, T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1396 · Cited by 609
Dams, E. T. M., Laverman, P., Oyen, W. J. G., Storm, G., Scherphof, G. L., van der Meer, J. W. M., Corstens, F. H. M., & Boerman, O. C. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35391-1 · Cited by 607
Patel, S., Ashwanikumar, N., Robinson, E., Xia, Y., Mihai, C., Griffith, J. P., Hou, S., Esposito, A. A., Ketova, T., Welsher, K., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14527-2 · Cited by 601
On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids
Hafez, I., Maurer, N., & Cullis, P. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301506 · Cited by 601
Opportunities and Challenges in the Delivery of mRNA-Based Vaccines
Wadhwa, A., Aljabbari, A., Lokras, A., Foged, C., & Thakur, A. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020102 · Cited by 584
Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids
Heyes, J., Palmer, L., Bremner, K., & MacLachlan, I. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.06.014 · Cited by 572
Self-citationYanez Arteta, M., Kjellman, T., Bartesaghi, S., Wallin, S., Wu, X., Kvist, A. J., Dabkowska, A., Székely, N., Radulescu, A., Bergenholtz, J., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1720542115 · Cited by 534
Thess, A., Grund, S., Mui, B. L., Hope, M. J., Baumhof, P., Fotin-Mleczek, M., & Schlake, T. (2015) · Molecular Therapy · doi:10.1038/mt.2015.103 · Cited by 513
The promise of mRNA vaccines: a biotech and industrial perspective
Jackson, N. A. C., Kester, K. E., Casimiro, D., Gurunathan, S., & DeRosa, F. (2020) · npj Vaccines · doi:10.1038/s41541-020-0159-8 · Cited by 498
Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy
Giles, A. J., Hutchinson, M.-K. N. D., Sonnemann, H. M., Jung, J., Fecci, P. E., Ratnam, N. M., Zhang, W., Song, H., Bailey, R., Davis, D., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0371-5 · Cited by 492
Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates
Dong, Y., Love, K. T., Dorkin, J. R., Sirirungruang, S., Zhang, Y., Chen, D., Bogorad, R. L., Yin, H., Chen, Y., Vegas, A. J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1322937111 · Cited by 488
The Proteolytic Activation Systems of Complement
Reid, K. B. M., & Porter, R. R. (1981) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.50.070181.002245 · Cited by 477
Geisbert, T. W., Lee, A. C., Robbins, M., Geisbert, J. B., Honko, A. N., Sood, V., Johnson, J. C., de Jong, S., Tavakoli, I., Judge, A., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60357-1 · Cited by 463
Szebeni, J. (2014) · Molecular Immunology · doi:10.1016/j.molimm.2014.06.038 · Cited by 457
Semple, S. C., Klimuk, S. K., Harasym, T. O., Dos Santos, N., Ansell, S. M., Wong, K. F., Maurer, N., Stark, H., Cullis, P. R., Hope, M. J., et al. (2001) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(00)00343-6 · Cited by 454
Linkage between endosomal escape of LNP-mRNA and loading into EVs for transport to other cells
Maugeri, M., Nawaz, M., Papadimitriou, A., Angerfors, A., Camponeschi, A., Na, M., Hölttä, M., Skantze, P., Johansson, S., Sundqvist, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12275-6 · Cited by 428
Scott, L. J. (2020) · Drugs · doi:10.1007/s40265-020-01269-0 · Cited by 420
Liang, F., Lindgren, G., Lin, A., Thompson, E. A., Ols, S., Röhss, J., John, S., Hassett, K., Yuzhakov, O., Bahl, K., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.08.006 · Cited by 395
Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA
Chen, S., Tam, Y. Y. C., Lin, P. J. C., Sung, M. M. H., Tam, Y. K., & Cullis, P. R. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.059 · Cited by 366
Ishida, T., Harada, M., Wang, X. Y., Ichihara, M., Irimura, K., & Kiwada, H. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.04.003 · Cited by 365
Leung, A. K. K., Hafez, I. M., Baoukina, S., Belliveau, N. M., Zhigaltsev, I. V., Afshinmanesh, E., Tieleman, D. P., Hansen, C. L., Hope, M. J., & Cullis, P. R. (2012) · The Journal of Physical Chemistry C · doi:10.1021/jp303267y · Cited by 360
Pardi, N., Secreto, A. J., Shan, X., Debonera, F., Glover, J., Yi, Y., Muramatsu, H., Ni, H., Mui, B. L., Tam, Y. K., et al. (2017) · Nature Communications · doi:10.1038/ncomms14630 · Cited by 352
Barcoded nanoparticles for high throughput in vivo discovery of targeted therapeutics
Dahlman, J. E., Kauffman, K. J., Xing, Y., Shaw, T. E., Mir, F. F., Dlott, C. C., Langer, R., Anderson, D. G., & Wang, E. T. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1620874114 · Cited by 335
Drug delivery to the posterior segment of the eye
Thrimawithana, T. R., Young, S., Bunt, C. R., Green, C., & Alany, R. G. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2010.12.004 · Cited by 335
Development of Lipidoid–siRNA Formulations for Systemic Delivery to the Liver
Akinc, A., Goldberg, M., Qin, J., Dorkin, J. R., Gamba-Vitalo, C., Maier, M., Jayaprakash, K. N., Jayaraman, M., Rajeev, K. G., Manoharan, M., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.36 · Cited by 323
The Mechanism of Detergent Solubilization of Liposomes and Protein-Containing Membranes
Kragh-Hansen, U., le Maire, M., & Møller, J. V. (1998) · Biophysical Journal · doi:10.1016/s0006-3495(98)77735-5 · Cited by 322
A modular platform for targeted RNAi therapeutics
Kedmi, R., Veiga, N., Ramishetti, S., Goldsmith, M., Rosenblum, D., Dammes, N., Hazan-Halevy, I., Nahary, L., Leviatan-Ben-Arye, S., Harlev, M., et al. (2018) · Nature Nanotechnology · doi:10.1038/s41565-017-0043-5 · Cited by 320
Sago, C. D., Lokugamage, M. P., Paunovska, K., Vanover, D. A., Monaco, C. M., Shah, N. N., Gamboa Castro, M., Anderson, S. E., Rudoltz, T. G., Lando, G. N., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1811276115 · Cited by 313
Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes
Veiga, N., Goldsmith, M., Granot, Y., Rosenblum, D., Dammes, N., Kedmi, R., Ramishetti, S., & Peer, D. (2018) · Nature Communications · doi:10.1038/s41467-018-06936-1 · Cited by 308
A Scalable, Extrusion-Free Method for Efficient Liposomal Encapsulation of Plasmid DNA
Jeffs, L. B., Palmer, L. R., Ambegia, E. G., Giesbrecht, C., Ewanick, S., & MacLachlan, I. (2005) · Pharmaceutical Research · doi:10.1007/s11095-004-1873-z · Cited by 307
Systemic delivery of factor IX messenger RNA for protein replacement therapy
Ramaswamy, S., Tonnu, N., Tachikawa, K., Limphong, P., Vega, J. B., Karmali, P. P., Chivukula, P., & Verma, I. M. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1619653114 · Cited by 301
Stabilized plasmid-lipid particles: construction and characterization
Wheeler, J. J., Palmer, L., Ossanlou, M., MacLachlan, I., Graham, R. W., Zhang, Y. P., Hope, M. J., Scherrer, P., & Cullis, P. R. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300821 · Cited by 299
Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication†
Morrissey, D. V., Blanchard, K., Shaw, L., Jensen, K., Lockridge, J. A., Dickinson, B., McSwiggen, J. A., Vargeese, C., Bowman, K., Shaffer, C. S., et al. (2005) · Hepatology · doi:10.1002/hep.20702 · Cited by 290
Wisse, E., Jacobs, F., Topal, B., Frederik, P., & De Geest, B. (2008) · Gene Therapy · doi:10.1038/gt.2008.60 · Cited by 289
Pardi, N., Parkhouse, K., Kirkpatrick, E., McMahon, M., Zost, S. J., Mui, B. L., Tam, Y. K., Karikó, K., Barbosa, C. J., Madden, T. D., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05482-0 · Cited by 281
Judge, A., McClintock, K., Phelps, J. R., & MacLachlan, I. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.09.014 · Cited by 280
Lipid Nanoparticle-Delivered Chemically Modified mRNA Restores Chloride Secretion in Cystic Fibrosis
Robinson, E., MacDonald, K. D., Slaughter, K., McKinney, M., Patel, S., Sun, C., & Sahay, G. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.05.014 · Cited by 272
Forty-Five Years of Marburg Virus Research
Brauburger, K., Hume, A. J., Mühlberger, E., & Olejnik, J. (2012) · Viruses · doi:10.3390/v4101878 · Cited by 268
Bray, M., & Geisbert, T. W. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.02.018 · Cited by 265
Systemic Messenger RNA Therapy as a Treatment for Methylmalonic Acidemia
An, D., Schneller, J. L., Frassetto, A., Liang, S., Zhu, X., Park, J.-S., Theisen, M., Hong, S.-J., Zhou, J., Rajendran, R., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.11.081 · Cited by 263
Lipid nanoparticles for delivery of messenger RNA to the back of the eye
Patel, S., Ryals, R. C., Weller, K. K., Pennesi, M. E., & Sahay, G. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.04.015 · Cited by 260
Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines
Lutz, J., Lazzaro, S., Habbeddine, M., Schmidt, K. E., Baumhof, P., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., Heidenreich, R., et al. (2017) · npj Vaccines · doi:10.1038/s41541-017-0032-6 · Cited by 257
Geisbert, T. W., Hensley, L. E., Kagan, E., Yu, E. Z., Geisbert, J. B., Daddario‐DiCaprio, K., Fritz, E. A., Jahrling, P. B., McClintock, K., Phelps, J. R., et al. (2006) · The Journal of Infectious Diseases · doi:10.1086/504267 · Cited by 254
Bioinspired Alkenyl Amino Alcohol Ionizable Lipid Materials for Highly Potent In Vivo mRNA Delivery
Fenton, O. S., Kauffman, K. J., McClellan, R. L., Appel, E. A., Dorkin, J. R., Tibbitt, M. W., Heartlein, M. W., DeRosa, F., Langer, R., & Anderson, D. G. (2016) · Advanced Materials · doi:10.1002/adma.201505822 · Cited by 252
Boosting intracellular delivery of lipid nanoparticle-encapsulated mRNA
Patel, S., Ashwanikumar, N., Robinson, E., DuRoss, A., Sun, C., Murphy-Benenato, K. E., Mihai, C., Almarsson, Ö., & Sahay, G. (2017) · Nano Letters · doi:10.1021/acs.nanolett.7b02664 · Cited by 251
Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates
Thi, E. P., Mire, C. E., Lee, A. C. H., Geisbert, J. B., Zhou, J. Z., Agans, K. N., Snead, N. M., Deer, D. J., Barnard, T. R., Fenton, K. A., et al. (2015) · Nature · doi:10.1038/nature14442 · Cited by 249
Parhiz, H., Shuvaev, V. V., Pardi, N., Khoshnejad, M., Kiseleva, R. Y., Brenner, J. S., Uhler, T., Tuyishime, S., Mui, B. L., Tam, Y. K., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.10.015 · Cited by 233
Song, L. Y., Ahkong, Q. F., Rong, Q., Wang, Z., Ansell, S., Hope, M. J., & Mui, B. (2002) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(01)00399-6 · Cited by 228
Rapidly produced SAM ® vaccine against H7N9 influenza is immunogenic in mice
Hekele, A., Bertholet, S., Archer, J., Gibson, D. G., Palladino, G., Brito, L. A., Otten, G. R., Brazzoli, M., Buccato, S., Bonci, A., et al. (2013) · Emerging Microbes & Infections · doi:10.1038/emi.2013.54 · Cited by 226
Kumar, V., Qin, J., Jiang, Y., Duncan, R. G., Brigham, B., Fishman, S., Nair, J. K., Akinc, A., Barros, S. A., & Kasperkovitz, P. V. (2014) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2014.61 · Cited by 222
RNA-Based Vaccines in Cancer Immunotherapy
McNamara, M. A., Nair, S. K., & Holl, E. K. (2015) · Journal of Immunology Research · doi:10.1155/2015/794528 · Cited by 221
mRNA Delivery for Therapeutic Anti-HER2 Antibody Expression In Vivo
Rybakova, Y., Kowalski, P. S., Huang, Y., Gonzalez, J. T., Heartlein, M. W., DeRosa, F., Delcassian, D., & Anderson, D. G. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.05.012 · Cited by 218
Semple, S. C., Harasym, T. O., Clow, K. A., Ansell, S. M., Klimuk, S. K., & Hope, M. J. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.078113 · Cited by 211
A Combinatorial Library of Lipid Nanoparticles for RNA Delivery to Leukocytes
Ramishetti, S., Hazan‐Halevy, I., Palakuri, R., Chatterjee, S., Naidu Gonna, S., Dammes, N., Freilich, I., Kolik Shmuel, L., Danino, D., & Peer, D. (2020) · Advanced Materials · doi:10.1002/adma.201906128 · Cited by 211
Systemic Gene Silencing in Primary T Lymphocytes Using Targeted Lipid Nanoparticles
Ramishetti, S., Kedmi, R., Goldsmith, M., Leonard, F., Sprague, A. G., Godin, B., Gozin, M., Cullis, P. R., Dykxhoorn, D. M., & Peer, D. (2015) · ACS Nano · doi:10.1021/acsnano.5b02796 · Cited by 210
Abrams, M. T., Koser, M. L., Seitzer, J., Williams, S. C., DiPietro, M. A., Wang, W., Shaw, A. W., Mao, X., Jadhav, V., Davide, J. P., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2009.208 · Cited by 209
Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes
Gan, L.-M., Lagerström-Fermér, M., Carlsson, L. G., Arfvidsson, C., Egnell, A.-C., Rudvik, A., Kjaer, M., Collén, A., Thompson, J. D., Joyal, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08852-4 · Cited by 207
Paunovska, K., Da Silva Sanchez, A. J., Sago, C. D., Gan, Z., Lokugamage, M. P., Islam, F. Z., Kalathoor, S., Krupczak, B. R., & Dahlman, J. E. (2019) · Advanced Materials · doi:10.1002/adma.201807748 · Cited by 205
Kose, N., Fox, J. M., Sapparapu, G., Bombardi, R., Tennekoon, R. N., de Silva, A. D., Elbashir, S. M., Theisen, M. A., Humphris-Narayanan, E., Ciaramella, G., et al. (2019) · Science Immunology · doi:10.1126/sciimmunol.aaw6647 · Cited by 202
Ambegia, E., Ansell, S., Cullis, P., Heyes, J., Palmer, L., & MacLachlan, I. (2005) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2005.02.001 · Cited by 202
Self-citationSedic, M., Senn, J. J., Lynn, A., Laska, M., Smith, M., Platz, S. J., Bolen, J., Hoge, S., Bulychev, A., Jacquinet, E., et al. (2018) · Veterinary Pathology · doi:10.1177/0300985817738095 · Cited by 195
Kauffman, K. J., Mir, F. F., Jhunjhunwala, S., Kaczmarek, J. C., Hurtado, J. E., Yang, J. H., Webber, M. J., Kowalski, P. S., Heartlein, M. W., DeRosa, F., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.09.006 · Cited by 190
Marcos-Contreras, O. A., Greineder, C. F., Kiseleva, R. Y., Parhiz, H., Walsh, L. R., Zuluaga-Ramirez, V., Myerson, J. W., Hood, E. D., Villa, C. H., Tombacz, I., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1912012117 · Cited by 185
Systemic messenger RNA as an etiological treatment for acute intermittent porphyria
Jiang, L., Berraondo, P., Jericó, D., Guey, L. T., Sampedro, A., Frassetto, A., Benenato, K. E., Burke, K., Santamaría, E., Alegre, M., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0199-z · Cited by 181
Basha, G., Novobrantseva, T. I., Rosin, N., Tam, Y. Y. C., Hafez, I. M., Wong, M. K., Sugo, T., Ruda, V. M., Qin, J., Klebanov, B., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.190 · Cited by 181
Webb, M. S., Saxon, D., Wong, F. M. P., Lim, H. J., Wang, Z., Bally, M. B., Choi, L. S. L., Cullis, P. R., & Mayer, L. D. (1998) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(98)00077-7 · Cited by 171
Clinical Aspects of Marburg Hemorrhagic Fever
Mehedi, M., Groseth, A., Feldmann, H., & Ebihara, H. (2011) · Future Virology · doi:10.2217/fvl.11.79 · Cited by 167
Lipid Nanoparticle Delivery of siRNA to Silence Neuronal Gene Expression in the Brain
Rungta, R. L., Choi, H. B., Lin, P. J., Ko, R. W., Ashby, D., Nair, J., Manoharan, M., Cullis, P. R., & MacVicar, B. A. (2013) · Molecular Therapy—Nucleic Acids · doi:10.1038/mtna.2013.65 · Cited by 165
Experimental Treatment of Ebola Virus Disease with TKM-130803: A Single-Arm Phase 2 Clinical Trial
Dunning, J., Sahr, F., Rojek, A., Gannon, F., Carson, G., Idriss, B., Massaquoi, T., Gandi, R., Joseph, S., Osman, H. K., et al. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1001997 · Cited by 165
MicroRNAs Enable mRNA Therapeutics to Selectively Program Cancer Cells to Self-Destruct
Jain, R., Frederick, J. P., Huang, E. Y., Burke, K. E., Mauger, D. M., Andrianova, E. A., Farlow, S. J., Siddiqui, S., Pimentel, J., Cheung-Ong, K., et al. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0734 · Cited by 164
Granot-Matok, Y., & Peer, D. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.08.015 · Cited by 161
Paunovska, K., Gil, C. J., Lokugamage, M. P., Sago, C. D., Sato, M., Lando, G. N., Gamboa Castro, M., Bryksin, A. V., & Dahlman, J. E. (2018) · ACS Nano · doi:10.1021/acsnano.8b03640 · Cited by 160
Lipid nanoparticles for short interfering RNA delivery
Leung, A. K. K., Tam, Y. Y. C., & Cullis, P. R. (2014) · Advances in genetics · doi:10.1016/b978-0-12-800148-6.00004-3 · Cited by 158
Chen, D., Ganesh, S., Wang, W., & Amiji, M. M. (2019) · Nanoscale · doi:10.1039/c8nr09855g · Cited by 158
Constrained Nanoparticles Deliver siRNA and sgRNA to T Cells In Vivo without Targeting Ligands
Lokugamage, M. P., Sago, C. D., Gan, Z., Krupczak, B. R., & Dahlman, J. E. (2019) · Advanced Materials · doi:10.1002/adma.201902251 · Cited by 157
Lai, I. K., Swaminathan, S., Baylot, V., Mosley, A. R., Dhanasekaran, R., Gabay, M., & Felsher, D. W. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0431-x · Cited by 154
Truong, B., Allegri, G., Liu, X.-B., Burke, K. E., Zhu, X., Cederbaum, S. D., Häberle, J., Martini, P. G. V., & Lipshutz, G. S. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1906182116 · Cited by 151
Stabilized plasmid-lipid particles for systemic gene therapy
Tam, P., Monck, M. A., Lee, D., Ludkovski, O., Leng, E. C., Clow, K. A., Stark, H., Scherrer, P., Graham, R. W., & Cullis, P. R. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301308 · Cited by 150
Flowers, S. A., & Rebeck, G. W. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104724 · Cited by 149
Targeted mRNA Therapy for Ornithine Transcarbamylase Deficiency
Prieve, M. G., Harvie, P., Monahan, S. D., Roy, D., Li, A. G., Blevins, T. L., Paschal, A. E., Waldheim, M., Bell, E. C., Galperin, A., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.12.024 · Cited by 145
Oral delivery of siRNA lipid nanoparticles: Fate in the GI tract
Ball, R. L., Bajaj, P., & Whitehead, K. A. (2018) · Scientific Reports · doi:10.1038/s41598-018-20632-6 · Cited by 145
Chen, D., Parayath, N. N., Ganesh, S., Wang, W., & Amiji, M. M. (2019) · Nanoscale · doi:10.1039/c9nr05788a · Cited by 141
Nabhan, J. F., Wood, K. M., Rao, V. P., Morin, J., Bhamidipaty, S., LaBranche, T. P., Gooch, R. L., Bozal, F., Bulawa, C. E., & Guild, B. C. (2016) · Scientific Reports · doi:10.1038/srep20019 · Cited by 140
Immunostimulating capacities of stabilized RNA molecules
Scheel, B., Braedel, S., Probst, J., Carralot, J., Wagner, H., Schild, H., Jung, G., Rammensee, H., & Pascolo, S. (2004) · European Journal of Immunology · doi:10.1002/eji.200324198 · Cited by 138
Calvente, C. J., Sehgal, A., Popov, Y. V., Kim, Y. O., Zevallos, V. F., Şahin, U., Diken, M., & Schuppan, D. (2015) · Hepatology · doi:10.1002/hep.27936 · Cited by 138
Saadati, R., Dadashzadeh, S., Abbasian, Z., & Soleimanjahi, H. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0934-y · Cited by 134
Lindgren, G., Ols, S., Liang, F., Thompson, E. A., Lin, A., Hellgren, F., Bahl, K., John, S., Yuzhakov, O., Hassett, K. J., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01539 · Cited by 132
Verbeke, R., Lentacker, I., Wayteck, L., Breckpot, K., Van Bockstal, M., Descamps, B., Vanhove, C., De Smedt, S. C., & Dewitte, H. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.041 · Cited by 132
Post-exposure treatments for Ebola and Marburg virus infections
Cross, R. W., Mire, C. E., Feldmann, H., & Geisbert, T. W. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.251 · Cited by 132
Mild Innate Immune Activation Overrides Efficient Nanoparticle‐Mediated RNA Delivery
Lokugamage, M. P., Gan, Z., Zurla, C., Levin, J., Islam, F. Z., Kalathoor, S., Sato, M., Sago, C. D., Santangelo, P. J., & Dahlman, J. E. (2020) · Advanced Materials · doi:10.1002/adma.201904905 · Cited by 126
Inclisiran—New hope in the management of lipid disorders?
Dyrbuś, K., Gąsior, M., Penson, P., Ray, K. K., & Banach, M. (2020) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2019.11.001 · Cited by 120
Stawicki, S. P., Kalra, S., Kelkar, D. S., Galwankar, S., Papadimos, T. J., Arquilla, B., Hoey, B., Sharpe, R., Sabol, D. M., & Jahre, J. A. (2014) · Journal of Global Infectious Diseases · doi:10.4103/0974-777x.145247 · Cited by 117
Conceição, M., Mendonça, L., Nóbrega, C., Gomes, C., Costa, P., Hirai, H., Moreira, J. N., Lima, M. C., Manjunath, N., & Pereira de Almeida, L. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2015.12.021 · Cited by 117
Origins and Evolution of Hepatitis B Virus and Hepatitis D VirusPreprint
Littlejohn, M., LOCARNINI, S. A., & Yuen, L. K. W. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a021360 · Cited by 112
DeRosa, F., Smith, L., Shen, Y., Huang, Y., Pan, J., Xie, H., Yahalom, B., & Heartlein, M. W. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.03.001 · Cited by 111
Besin, G., Milton, J., Sabnis, S., Howell, R. D., Mihai, C., Burke, K. E., Benenato, K. E., Stanton, M., Smith, P., Senn, J. J., et al. (2019) · ImmunoHorizons · doi:10.4049/immunohorizons.1900029 · Cited by 111
Ebola virus disease outbreak in Nigeria: Transmission dynamics and rapid control
Althaus, C. L., Low, N. N., Musa, E., Shuaib, F. M. B., & Gsteiger, S. (2015) · Epidemics · doi:10.1016/j.epidem.2015.03.001 · Cited by 106
Main trends of immune effects triggered by nanomedicines in preclinical studies
Halamoda‐Kenzaoui, B., & Bremer‐Hoffmann, S. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s168808 · Cited by 106
Sato, Y., Matsui, H., Yamamoto, N., Sato, R., Munakata, T., Kohara, M., & Harashima, H. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.044 · Cited by 105
Kauffman, K. J., Oberli, M. A., Dorkin, J. R., Hurtado, J. E., Kaczmarek, J. C., Bhadani, S., Wyckoff, J., Langer, R., Jaklenec, A., & Anderson, D. G. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.11.005 · Cited by 105
Katakowski, J. A., Mukherjee, G., Wilner, S. E., Maier, K. E., Harrison, M. T., DiLorenzo, T. P., Levy, M., & Palliser, D. (2015) · Molecular Therapy · doi:10.1038/mt.2015.175 · Cited by 104
Andresen, T. L., Bruun, J., Larsen, T. B., Jølck, R. I., Eliasen, R., Holm, R., & Gjetting, T. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s87334 · Cited by 100
Oral delivery of non-viral nucleic acid-based therapeutics - do we have the guts for this?
O’Driscoll, C. M., Bernkop‐Schnürch, A., Friedl, J. D., Véronique Préat, A., & Jannin, V. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.03.027 · Cited by 99
Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo
Jyotsana, N., Sharma, A. K., Chaturvedi, A., Budida, R., Scherr, M., Kuchenbauer, F. C., Lindner, R. M., Noyan, F., Sühs, K., Stangel, M., et al. (2019) · Annals of Hematology · doi:10.1007/s00277-019-03713-y · Cited by 99
Marburg virus infection in nonhuman primates: Therapeutic treatment by lipid-encapsulated siRNA
Thi, E. P., Mire, C. E., Ursic-Bedoya, R. J., Geisbert, J. B., Lee, A. C. H., Agans, K. N., Robbins, M., Deer, D. J., Fenton, K. A., MacLachlan, I., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009706 · Cited by 90
Long-term efficacy and safety of mRNA therapy in two murine models of methylmalonic acidemia
An, D., Frassetto, A., Jacquinet, E., Eybye, M., Milano, J., DeAntonis, C., Nguyen, V., Laureano, R., Milton, J., Sabnis, S., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.07.003 · Cited by 87
Testing thousands of nanoparticles in vivo using DNA barcodes
Lokugamage, M. P., Sago, C. D., & Dahlman, J. E. (2018) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2018.08.001 · Cited by 87
Tanaka, H., Nakatani, T., Furihata, T., Tange, K., Nakai, Y., Yoshioka, H., Harashima, H., & Akita, H. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b01084 · Cited by 82
Li, F., Li, Q., Wang, J., Zhan, C., Xie, C., & Lu, W. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.12.023 · Cited by 80
Lipid Encapsulation Enables the Effective Systemic Delivery of Polyplex Plasmid DNA
Heyes, J. A., Palmer, L., Chan, K., Giesbrecht, C., Jeffs, L. B., & MacLachlan, I. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300101 · Cited by 78
Self-citationHuey, R., Hawthorne, S. J., & McCarron, P. A. (2016) · Journal of drug targeting · doi:10.1080/1061186x.2016.1223676 · Cited by 77
Tao, W., Mao, X., Davide, J. P., Ng, B., Cai, M., Burke, P. A., Sachs, A. B., & Sepp‐Lorenzino, L. (2010) · Molecular Therapy · doi:10.1038/mt.2010.282 · Cited by 73
Qiao, J.-B., Fan, Q., Zhang, C., Lee, J., Byun, J., Xing, L., Gao, X., Oh, Y., & Jiang, H. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.02.049 · Cited by 73
Hyaluronan grafted lipid-based nanoparticles as RNAi carriers for cancer cells
Landesman‐Milo, D., Goldsmith, M., Ben‐Arye, S. L., Witenberg, B., Brown, E., Leibovitch, S., Azriel, S., Tabak, S., Morad, V., & Peer, D. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.08.024 · Cited by 68
Jia, Z., Gong, Y. Q., Pi, Y., Liu, X., Gao, L., Kang, L., Wang, J., Yang, F., Tang, J., Lu, W., et al. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00709 · Cited by 68
Chen, S., Zaifman, J., Kulkarni, J. A., Zhigaltsev, I. V., Tam, Y. K., Ciufolini, M. A., Tam, Y. Y. C., & Cullis, P. R. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.07.026 · Cited by 68
Adjuvant incorporated lipid nanoparticles for enhanced mRNA-mediated cancer immunotherapy
Lee, K., Kim, S. Y., Seo, Y., Kim, M. H., Chang, J., & Lee, H. (2019) · Biomaterials Science · doi:10.1039/c9bm01564g · Cited by 65
Broering, R., Real, C. I., John, M., Jahn‐Hofmann, K., Ickenstein, L. M., Kleinehr, K., Paul, A., Sutter, K., Dittmer, U., Gerken, G., et al. (2013) · International Immunology · doi:10.1093/intimm/dxt040 · Cited by 62
Ursic-Bedoya, R. J., Mire, C. E., Robbins, M., Geisbert, J. B., Judge, A. D., MacLachlan, I., & Geisbert, T. W. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit465 · Cited by 61
ARB-1740, a RNA Interference Therapeutic for Chronic Hepatitis B Infection
Thi, E. P., Dhillon, A. P., Ardzinski, A., Bidirici-Ertekin, L., Cobarrubias, K. D., Cuconati, A., Kondratowicz, A. S., Kwak, K., Li, A. H. L., Miller, A., et al. (2018) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.8b00191 · Cited by 60
Rescue of non-human primates from advanced Sudan ebolavirus infection with lipid encapsulated siRNA
Thi, E. P., Lee, A. C. H., Geisbert, J. B., Ursic-Bedoya, R. J., Agans, K. N., Robbins, M., Deer, D. J., Fenton, K. A., Kondratowicz, A. S., MacLachlan, I., et al. (2016) · Nature Microbiology · doi:10.1038/nmicrobiol.2016.142 · Cited by 58
Delivery of siRNA Using Lipid Nanoparticles Modified with Cell Penetrating Peptide
Li, Y., Lee, R. J., Yu, K., Bi, Y., Qi, Y., Sun, Y., Li, Y., Xie, J., & Teng, L. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b09991 · Cited by 58
Liposomal Formulations for Nucleic Acid Delivery
MacLachlan, I. (2007) · CRC Press eBooks · doi:10.1201/9780849387951-16 · Cited by 57
A daunting task: manipulating leukocyte function with RNA i
Peer, D. (2013) · Immunological Reviews · doi:10.1111/imr.12044 · Cited by 57
Luo, F., Zheng, L., Hu, Y., Liu, S., Wang, Y., Xiong, Z., Hu, X., & Tan, F. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.00605 · Cited by 57
Balakrishnan, B., An, D., Nguyen, V., DeAntonis, C. M., Martini, P. G. V., & Lai, K. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.09.018 · Cited by 57
Yanagi, T., Tachikawa, K., Wilkie-Grantham, R. P., Hishiki, A., Nagai, K., Toyonaga, E., Chivukula, P., & Matsuzawa, S. (2016) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2016.40 · Cited by 55
Cell Subtypes Within the Liver Microenvironment Differentially Interact with Lipid Nanoparticles
Sago, C. D., Krupczak, B. R., Lokugamage, M. P., Gan, Z., & Dahlman, J. E. (2019) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-019-00573-4 · Cited by 55
Lipid‐Like Nanoparticles for Small Interfering RNA Delivery to Endothelial Cells
Cho, S., Goldberg, M. S., Son, S. M., Xu, Q., Yang, F., Mei, Y., Bogatyrev, S. R., Langer, R., & Anderson, D. G. (2009) · Advanced Functional Materials · doi:10.1002/adfm.200900519 · Cited by 52
Encapsulation of high molecular weight DNA in large unilamellar phospholipid vesicles
Mannino, R. J., Allebach, E. S., & Strohl, W. A. (1979) · FEBS Letters · doi:10.1016/0014-5793(79)81014-5 · Cited by 44
Identification of Novel Fibrosis Modifiers by In Vivo siRNA Silencing
Vollmann, E. H., Cao, L., Amatucci, A., Reynolds, T. L., Hamann, S., Dalkilic-Liddle, I., Cameron, T. O., Hoßbach, M., Kauffman, K. J., Mir, F. F., et al. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.04.014 · Cited by 42
siRNA rescues nonhuman primates from advanced Marburg and Ravn virus disease
Thi, E. P., Mire, C. E., Lee, A. C. H., Geisbert, J. B., Ursic-Bedoya, R. J., Agans, K. N., Robbins, M., Deer, D. J., Cross, R. W., Kondratowicz, A. S., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci96185 · Cited by 41
Sakurai, Y., Mizumura, W., Murata, M., Hada, T., Yamamoto, S., Ito, K., Iwasaki, K., Katoh, T., Goto, Y., Takagi, A., et al. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00362 · Cited by 39
Huang, X., & Chau, Y. (2019) · Experimental Eye Research · doi:10.1016/j.exer.2019.107711 · Cited by 37
Entrapment of ribonucleic acids in liposomes
Dimitriadis, G. (1978) · FEBS Letters · doi:10.1016/0014-5793(78)80582-1 · Cited by 34
Pathogenicity Comparison Between the Kikwit and Makona Ebola Virus Variants in Rhesus Macaques
Wong, G., Qiu, X., Vega, M.-A. D. L., Fernando, L., Wei, H., Bello, A., Fausther‐Bovendo, H., Audet, J., Kroeker, A., Kozak, R. A., et al. (2016) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiw267 · Cited by 33
Repeat Injection Studies of Technetium-99M-Labeled Peg-Liposomes in the Same Animal
Coins, B., Phillips, W. T., & Klipper, R. W. (1998) · Journal of Liposome Research · doi:10.3109/08982109809035531 · Cited by 31
Akita, H., Nakatani, T., Kuroki, K., Maenaka, K., Tange, K., Nakai, Y., & Harashima, H. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.05.043 · Cited by 30
Ebolavirus: A Brief Review of Novel Therapeutic Targets
(2011) · doi:10.2217/fmb.11.110 · Cited by 30
Toriyabe, N., Sakurai, Y., Kato, A., Yamamoto, S., Tange, K., Nakai, Y., Akita, H., & Harahsima, H. (2017) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2017.04.042 · Cited by 29
Ye, X., Tateno, C., Thi, E. P., Kakuni, M., Snead, N. M., Ishida, Y., Barnard, T. R., Sofia, M. J., Shimada, T., & Lee, A. C. H. (2018) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.8b00192 · Cited by 28
Current Status of Messenger RNA Delivery Systems
Stanton, M. G. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0726 · Cited by 26
Lipidoid mRNA Nanoparticles for Myocardial Delivery in Rodents
Turnbull, I. C., Eltoukhy, A. A., Anderson, D. G., & Costa, K. D. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6588-5_10 · Cited by 25
Han, L., Campanucci, V. A., Cooke, J., & Salter, M. W. (2013) · Molecular Brain · doi:10.1186/1756-6606-6-36 · Cited by 18
Development and clinical applications of siRNA-encapsulated lipid nanoparticles in cancer
Lin, P. J. C., Tam, Y. K., & Cullis, P. R. (2014) · Clinical Lipidology · doi:10.2217/clp.14.27 · Cited by 18
Fan, Q.-W., Iosbe, I., Asou, H., Yanagisawa, K., & Michikawa, M. (2001) · AGE · doi:10.1007/s11357-001-0001-9 · Cited by 13
Conceição, M., Mendonça, L. S., Nóbrega, C., et al. (2016) · Data in Brief · doi:10.1016/j.dib.2016.01.017 · Cited by 13
Inclisiran: UK to roll out new cholesterol lowering drug from next year
Iacobucci, G. (2020) · BMJ · doi:10.1136/bmj.m139 · Cited by 11
Hoerr, I. (2000) · doi:10.1002/1521-4141(200001)30:1
Cited by
Vaccine adjuvants: mechanisms and platforms
Zhao, T., Cai, Y., Jiang, Y., He, X., Wei, Y., Yu, Y., & Tian, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01557-7 · Cited by 1,020
Dilliard, S. A., & Siegwart, D. J. (2023) · Nature Reviews Materials · doi:10.1038/s41578-022-00529-7 · Cited by 671
Ndeupen, S., Qin, Z., Jacobsen, S., Bouteau, A., Estanbouli, H., & Igyártó, B. Z. (2021) · iScience · doi:10.1016/j.isci.2021.103479 · Cited by 678
Unlocking the promise of mRNA therapeutics
Rohner, E., Yang, R., Foo, K. S., Goedel, A., & Chien, K. R. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01491-z · Cited by 612
Thi, T. T. H., Suys, E. J. A., Lee, J. S., Nguyen, D. H., Park, K. D., & Truong, N. P. (2021) · Vaccines · doi:10.3390/vaccines9040359 · Cited by 525
Metadata
- Authors
- Samaridou, E., Heyes, J., & Lutwyche, P.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2020
- Volume
- 154-155
- Pages
- 37-63
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W3035225041
- Cited by
- 583
- References
- 188
- FWCI
- 5.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.